Argus Partners Advises Eyestem Research Private Limited, In Connection With Its Latest Fund Raising From Endiya Partners
LIVELAW NEWS NETWORK
3 Jun 2021 5:41 PM IST
Argus Partners
Argus Partners has acted for Eyestem Research Private Limited, a Bengaluru based cell therapy company in connection with its latest fund raising from Endiya Partners, a venture capital fund that focuses on investing in firms in technology, healthcare and life sciences.
As per the CEO and Founder of Eyestem, this funding would help them in scaling up their operations and creating affordable cell therapies.
Eyecyte RPE, the company's patented flagship product, is close to finding a treatment for Dry AMD and the company has two more products in the pipeline for similar incurable diseases affecting humanity. Last year, the company received manufacturing approval for Eyecyte RPE from the Indian regulators and is in the process of manufacturing the product for confirmatory efficacy and toxicity studies in animals. Phase 1 human clinical trials for Eyecyte RPE are currently scheduled for early 2022.
The Argus Team was led by Vinod Joseph and Suchita Ambadipudi (Partners) along with Smriti Tripathi, Protiti Basu, Pranav Pillai and Anurag Prasad (Associates).
